The properties of inhaled corticosteroids: Similarities and differences

Primary Care Respiratory Journal

Volumn 16, Issue 3, 2007, Pages 149-154

  Barnes, Neil C ^a,b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

Comparison; Efficacy; Inhaled corticosteroids; Properties; Side effects

Indexed keywords

ANTIFUNGAL AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; PLACEBO; STEROID; TRIAMCINOLONE; TRIAMCINOLONE ACETATE;

ADRENAL CORTEX SUPPRESSION; ASTHMA; BONE DENSITY; CAPILLARY RESISTANCE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DYSPHONIA; ENDOCRINE DISEASE; FRACTURE; GLAUCOMA; GROWTH RETARDATION; HOARSENESS; HUMAN; HYPERTENSION; INHALER; LUNG INFARCTION; OSTEOPOROSIS; PURPURA; REVIEW; SIDE EFFECT; SKIN DISEASE; SKIN THINNING; THRUSH; WEIGHT GAIN;

ADMINISTRATION, INHALATION; ADRENAL GLANDS; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BONE AND BONES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; GROWTH; HOARSENESS; HUMANS; NEBULIZERS AND VAPORIZERS; PRACTICE GUIDELINES; PREGNENEDIONES;

EID: 34249996731     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.3132/pcrj.2007.00038     Document Type: Review

References (33)

1. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline for management of asthma. Thorax 2003;58(suppl 1):1-94.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma management and Prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute, 2002. Publication no. 02-3659.
3. Suissa S, Ernst P, Kezouh A. Regular use of inhaled coritcosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002;57:880-4.
4. Ernst P, Spritzer WD, Suissa S et al. Risk of fatal and near fatal asthma in relation to inhaled corticosteroid use. JAMA 1992;268:3462-4.
5. Belvisi MG, Bundschuh DS, Stoeck M, et al. Preclinical profile of ciclesonide, a novel corticosteroid for the treatment of asthma. J Pharmacol Exp Ther 2005;314:568-74.
6. Adams N, Bestall JM, Lasserson TJ, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. The Cochrane Library (ISSN 1464-780X).
7. Kalliner MA. Pharmacological characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate. Clin Ther 2006;28:319-31.
8. Brutsche MH, Brutsche IC, Munawar M et al. A Comparison of pharmacokinetics and systemic effects of inhaled fluticasone a propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000;356:556-61.
9. Harrison TW, Wisniewski A, Honour J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001;56:186-91.
10. Harrison TW, Tattersfield AE. Plasma concentration of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003;58:258-60.
11. Nave R, Gunawardena KA, Zech K, Bethke TD. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther 2006;44:1-7.
12. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457-61.
13. Mortimer KJ, Tata LJ, Smith CJ et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006;61:405-08.
14. Weinbrenner A, Huneke D, Zschiesche M et al. Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002;87:2160-3.
15. Pauwels RA, Lofdahl CG, Laitinen LA et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999;340:1948-53.
16. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-09.
17. Scanlon, PD. Connett JE, Wise RA et al and the Lung Health Research Group. Loss of Bone Density with inhaled Triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004;170:1302-09.
18. Jones A, Fay JK, Burr M, Stone M, Hood K, Roberts G. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. The Cochrane Library (ISSN 1464-780X).
19. Calverley PM, Anderson JA, Celli B et al; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
20. Wong CA, Walsh LJ, Smith CJ et al. Inhaled corticosteroids use and bonemineral density in patients with asthma. Lancet 2000;355: 1399-403.
21. Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A. Use of inhaled corticosteroids and the risk of bone fracture. Chest 2006;130:1082-8.
22. Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004;169:83-6.
23. Simons FER, Persuad MP, Gillespie CA, Cheang M, Shuckett EP. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucorticosteroids. Lancet 1993;342:776-8.
24. Cumming RG, Mitchell P, Leeder SR. Use of Inhaled Corticosteroids and the Risk of Cataracts. N Engl J Med 1997;337:8-14.
25. Bahceclier NN, Nuhoglu Y, Nursoy MA, Kodalli N, Barlan IB, Basaran MM. Inhaled corticosteroid therapy is safe in tuberculin-positive asthmatic children. Pediatr Infect Dis J 2000;19:215-18.
26. Agertoft L, Pederson S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a close-response study. Eur Resp J 1997;10:1507-12.
27. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986;61:1049-55.
28. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000;343:1054-63.
29. Pauwels RA, Pedersen S, Busse WW et al, START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomised, doubleblind trial. Lancet 2003;361:1071-6.
30. Sorkness CA, Lemanske RF Jr, Mauger DT, et al; The Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. J Allergy Clin Immunol 2007;119:64-72.
31. Ferguson AC, Van Bever HO, Teper AM, Lasytsya O, Goldfrad CH, Whitehead PJ. A comparison of the relative growth velocities with budesonide and fluticasone propionate in children with asthma. Respir Med 2007;101:118-29.
32. Pedersen S, Garcia-Garcia ML, Manjra A, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006;41:954-61.
33. Lipworth BJ, Jackson CM. Pharmacokinetics of Chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclamethasone dipropionate. Br J Clin Pharmacol 1999;48:866-8.